6Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies: part Ⅰ. Circulation,2003,108 ( 14 ) : 1664 - 1672. 被引量：1
7Zeng B,Prasan A,Fung KC,et al. Elevated circulating levels of matrix metalloproteinase -9 and -2 in patients with symptomatic coronary artery disease. Intern Med J,2005,35 ( 6 ) :331 - 335. 被引量：1
8Handa N, Matsumotom, Maede H, et al, lsehemic stroke events and caeotid atherosclerosis. Stroke, 1995,26 ( 10 ) : 1781 - 1786. 被引量：1
9Jo Y, Ycon J, Kim HJ,et al. Analysis of tissue inhibitor of metalloproteinases- 2 effect on pro- matrix metalloproteinase- 2 activation by membrane - type 1 matrix metalloproteinase using baculovirus/insect - cell expression system. Biochem J,2000,345 : 511 - 519. 被引量：1
10Lee E, Grodzinsky A J, Libby P,et al. Human vascular smooth muscle cell- monocyte interactions and metalloproteinase secretion in culture. Arterioscler Thromb Vasc Biol, 1995,15:2284 - 2289. 被引量：1
